GlassScriptPhysician profile
Gabrielle Michelle Jimenez
NPI 1477265866
$1,674.12
in general payments reported to CMS, 2019-2025
18 companies · $1,043 in 2025
The $1,043 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $631 · 2025: $1,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,674.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,674.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $398.31 | 2025 | Spravato |
| Pharmacosmos Therapeutics INC. | $194.80 | 2024-2025 | Monoferric |
| Novartis Pharmaceuticals Corporation | $149.78 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $124.97 | 2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $123.83 | 2025 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $118.64 | 2025 | |
| Acadia Pharmaceuticals INC | $113.68 | 2024 | Nuplazid |
| Amgen INC. | $110.18 | 2024-2025 | Krystexxa |
| Organon LLC | $72.68 | 2025 | Nexplanon |
| Baxter Healthcare | $57.09 | 2024 | Hillrom - Monarch Airway Clearance System |
| Glaxosmithkline, LLC. | $44.77 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $42.54 | 2025 | |
| Edwards Lifesciences Corporation | $24.67 | 2024 | |
| Novo Nordisk INC | $23.97 | 2024 | Rybelsus, Ozempic |
| Abbvie INC. | $21.85 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $20.24 | 2024 | Intellis Adaptivestim |
| Alkermes, INC. | $16.22 | 2025 | Vivitrol |
| Eisai INC. | $15.90 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabrielle Jimenez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.